Max Planck Institute for Molecular Genetics, Berlin D-14195, and Institute of Human Genetics, University Medicine, Mainz D-55131, Germany.
Departments of Pediatrics and Human Genetics, Emma Children's Hospital, Amsterdam University Medical Centers, NL-1105 AZ Amsterdam, The Netherlands.
Cold Spring Harb Mol Case Stud. 2022 Mar 24;8(2). doi: 10.1101/mcs.a006210. Print 2022 Feb.
After a long and largely disappointing detour, Genome Research has reidentified Rare Diseases as a major opportunity for improving health care and a clue to understanding gene and genome function. In this Special Issue of on Rare Diseases, several invited Perspectives, numerous Case Reports, and this Editorial itself address recent breakthroughs as well as unsolved problems in this wide field. These range from exciting prospects for gap-free diagnostic whole-genome sequencing to persisting problems related to identifying and distinguishing pathogenic and benign variants; and from the good news that soon, the United Kingdom will no longer be the only country to have introduced whole-genome sequencing into health care to the sobering conclusion that in many countries the clinical infrastructure for bringing Genome Medicine to the patient is still lacking. With less than 5000 genes firmly implicated in disease, the identification of at least twice as many disease genes is a major challenge, and the elucidation of their function is an even larger task. But given the renewed interest in rare diseases, their importance for health care, and the vast and growing spectrum of concepts and methods for studying them, the future of Human Genome Research is bright.
经过漫长而令人失望的迂回之后,《基因组研究》重新将罕见病确定为改善医疗保健的主要机会,也是了解基因和基因组功能的线索。本期《罕见病专刊》中的几篇特邀观点文章、大量病例报告以及本社论本身,探讨了这一广阔领域的最新突破和未解决的问题。这些问题包括从无间隙诊断全基因组测序的令人兴奋的前景到与识别和区分致病和良性变体相关的持续存在的问题;从好消息,即英国将不再是唯一将全基因组测序引入医疗保健的国家,到令人清醒的结论,即许多国家仍缺乏将基因组医学带给患者的临床基础设施。在与疾病密切相关的不到 5000 个基因中,至少还需要确定两倍数量的疾病基因,而阐明它们的功能则是更大的任务。但是,鉴于人们对罕见病的重新关注、它们对医疗保健的重要性以及研究它们的大量不断发展的概念和方法,人类基因组研究的未来是光明的。